Latanoprost insert

Drug Profile

Latanoprost insert

Alternative Names: Eye-D® latanoprost; Subconjunctival latanoprost controlled release insert; VS 101 insert

Latest Information Update: 07 Sep 2016

Price : $50

At a glance

  • Originator ViSci
  • Class Antiglaucomas; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Glaucoma

Most Recent Events

  • 07 Sep 2016 Latanoprost insert is still in phase I/II trials for Glaucoma in USA (Subconjunctival)
  • 30 Jun 2014 Phase-I/II clinical trials in Glaucoma in USA (Subconjunctival)
  • 20 May 2014 ViSci plans a phase I/IIa trial for Glaucoma in the USA (NCT02129673)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top